Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • News and press coverage
    • Stock information
    • Governance
    • Documentation

Corporate

06 September 2021

UK MHRA grants GenSight Biologics’ LUMEVOQ® ophthalmic gene therapy Promising Innovative Medicine designation

07 Sep 2021

Redburn Gene Therapy Virtual Summit 2021

01 September 2021

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

29 July 2021

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update

20 Jul 2021

OIS European Innovation Showcase – Virtual

07 Jul 2021

French Retail Investors Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

09 Jul 2021

KOL Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

05 July 2021

GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

05 July 2021

GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France

30 June 2021

GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 13
  • View next 9 articles
© 2022 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page